Dr David Smith advocates a shift away from stents that involve the need for dual-antiplatelet therapy.

[more]

"Europe has continued to be the stage upon which major developments with this technology have debuted," Dr Martyn Thomas claims.

[more]

Hannu Romppanen and Matti Niemelä discuss the use of the Promus Element everolimus-eluting stent system

[more]

A study presented at ACC 2010 has shown that lighter control of heart rate can be as effective as strict control

[more]

Francesco Prati discusses how drug-eluting stents have been found to dramatically reduce the incidence of restenosis.

[more]

Prof D. Carrié speaks to Cardiovascular News about progress in percutaneous coronary intervention.

[more]

Josep Brugada speaks to Cardiovascular News about his career, his proudest moments and his association with Barcelona FC.

[more]

Alfredo R Galassi, director of diagnostic and cardiovascular interventional laboratory, Ferrarotto Hospital University of Catania, Italy, and associate professor of cardiology, University of Catania, Italy, tells Cardiovascular News International about his career journey to date, and his love of sailing

[more]

Silvia G Priori spoke to Cardiovascular News about her career, research, joy in spending time with her two children, and the occasion she took beta-blockers before meeting Dr Mike Rosen.

[more]

Cardiovascular News talks to Professor Christian Hamm, Bad Nauheim, Germany, about his influences, current areas of research, and the challenges facing cardiology.

[more]

InfraReDx, Inc has announced clearance from the US FDA to market LipiScan IVUS, thus being the first catheter to combine near-infrared spectroscopy with intravascular ultrasound a valuable new tool to characterise coronary plaque and improve coronary stenting.

[more]

The FDA has approved an Investigational device exemption supplement that allows HeartWare to enroll a second allotment of 54 patients in its ADVANCE bridge-to-transplant clinical trial, which is designed to evaluate the HeartWare® Ventricular Assist System for patients with end-stage heart failure.

[more]

"Superior deliverability" distinguishes new medical drug-eluting stent for coronary artery disease from rivals, according to the company.

[more]

The Taxus Element Stent System is the company’s third-generation drug-eluting stent (DES) technology; it received CE mark approval in May.

[more]